dihexa bioavailability Dihexa (PNB-0408) | c-Met/HGFR Activator

This is the sharpest single difference in the comparison, and it colors every downstream statement about dosing and safety

Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation

Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway

Potential Benefits Works through amylin receptors rather than GLP-1, offering an alternative pathway for patients who may not respond optimally to GLP-1 medications alone

The clinical consequences could range from local inflammation or rash through to serious health issues, such as systemic hypersensitivity, including anaphylaxis, or antibody formation

Cardiovasc Res 36:276281 Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M et al (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2